EMEA-002723-PIP01-19-M02 - paediatric investigation plan
Sebetralstat
PIPHuman
Key facts
- Active Substance
- Sebetralstat
- Therapeutic area
- Congenital, familial and genetic disorders
- Decision number
- P/0476/2023
- PIP number
- EMEA-002723-PIP01-19-M02
- Pharmaceutical form(s)
- Film-coated tablet
- Age-appropriate oral solid dosage form
- Condition(s) / indication(s)
- Treatment of hereditary angioedema
- Route(s) of administration
- Oral use
- Contact for public enquiries
KalVista Pharmaceuticals Ltd
E-mail: regulatory@kalvista.com
Tel: +44 1980753002- Decision type
- PM: decision on the application for modification of an agreed PIP
- Decision date